Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Supernus Resubmits NDA for SPN-812 for ADHD in Pediatric Patients

americanpharmaceuticalreviewFebruary 10, 2021

Tag: SPN-812 , ADHD , Supernus

PharmaSources Customer Service